H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 1,604,590 | $37,691,819 | 0.16% | |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 1,553,748 | $36,497,541 | 0.73% | |
| 3. | RA Capital Management Peter Kolchinsky | 1,020,410 | $23,969,431 | 0.24% | |
| 4. | Parkman Healthcare Partners Greg Martinez | 796,256 | $18,704,053 | +11% | 1.68% |
| 5. | Millennium Management Israel Englander | 490,137 | $11,513,318 | +65% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 2,295,920 | $0.00 | 4,505,391 | 2025-08-08 | Filing | |
| $15.61 | 3,202 | $49,997.63 | 3,202 | 2024-12-30 | Filing | |
| $21.37 | 940,499 | $20,098,463.63 | 2,209,471 | 2024-12-19 | Filing | |
| $14.85 | 5,000 | $74,250.00 | 728,113 | 2024-11-25 | Filing | |
| $15.00 | 2,976 | $44,640.00 | 723,113 | 2024-11-25 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.35 | 9 | $183.13 | 17,673 | 2026-11-02 | Filing | |
| $19.61 | 718 | $14,078.33 | 17,682 | 2026-11-02 | Filing | |
| $20.35 | 29 | $590.09 | 59,257 | 2026-11-02 | Filing | |
| $19.61 | 2,564 | $50,274.14 | 59,286 | 2026-11-02 | Filing | |
| $20.35 | 29 | $590.09 | 53,800 | 2026-11-02 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,977,089 | $116,911,821 | 7.99% | |
| 2. | 1,488,018 | $34,953,543 | 0% | |
| 3. | 602,932 | $14,162,873 | 0% | |
| 4. | 559,590 | $13,144,769 | 0% | |
| 5. | 417,441 | $9,805,689 | 1.92% |